Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
When 70% of antibiotic users took a 3-strain Lactobacillus probiotic preparation the hospital-wide rate of healthcare-associated Clostridioides difficile infection improved significantly. The incidence of C. difficile infection for those taking the probiotic along with multiple antibiotics or a single high-risk antibiotic was decreased by at least half.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Hospital-wide rate of primary healthcare-associated Clostridioides difficile (HA-CDI) cases (A) and recurrent CDI episodes (B) per 10 000 patient-days (pt-days) for each semiannual period. The semiannual periods refer to hospital data from the spring through summer [Periods 1-7] or from the autumn through winter [Periods 8-13]. Error bars for simple proportion represent 95% confidence intervals calculated with Fisher exact test. *P < .01 for hospital-wide rate of primary HA-CDI cases versus 1 year earlier; †P < .01 for hospital-wide rate of primary HA-CDI cases versus 1 and 2 years earlier; ‡P < .01 for hospital-wide rate of first recurrent HA-CDI cases versus 1 and 2 years earlier.](https://figures.cochat.ai/paper-figures/df908cbbe9c446beb31a06714d9cafe8/enhanced-i-clostridioides-difficile-i-infection-prevention-with-a-pharmacy-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nor in 4543 patients (from 2016–2019) [66].”
From Lactobacillus Bacteremia and Probiotics: A Review (2023) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ogrinc, G., Davies, L., Goodman, D., Batalden, P., Davidoff, F., & Stevens, D. (2016) · BMJ Quality & Safety · doi:10.1136/bmjqs-2015-004411 · Cited by 2,996
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy149 · Cited by 1,160
The effect of antibiotics on the composition of the intestinal microbiota—a systematic review
Zimmermann, P., & Curtis, N. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.008 · Cited by 383
Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318 · cited 1×
“Eligible adults took 1 capsule (adults aged ≤49 years) or 2 capsules (adult aged ≥50 years) daily of a probiotic including Lactobacillus acidophilus CL1285, Lacticaseibacillus (Lactobacillus) casei LBC80R, and Lacticaseibacillus (Lactobacillus) rhamnosus CLR2 (Bio-K+ 50 Billion [50 billion colony-forming units per cap…”
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide
Sniffen, J. C., McFarland, L. V., Evans, C. T., & Goldstein, E. J. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209205 · Cited by 265 · cited 1×
“Probiotics, formulations comprising live microorganisms, offer another complementary approach and aim to improve a patient’s defenses to CDI [5].”
Self-citationPathway to Prevention of Nosocomial Clostridium difficile Infection
Goldstein, E. J. C., Johnson, S., Maziade, P.-J., McFarland, L. V., Trick, W. E., Dresser, L., Millette, M., Mazloum, H., & Low, D. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ142 · Cited by 70
Self-citationMcFarland, L. V., Ship, N., Auclair, J., & Millette, M. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.04.017 · Cited by 62
Self-citationMaziade, P.-J., Pereira, P., & Goldstein, E. J. C. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ178 · Cited by 60 · cited 3×
“Eligible adults took 1 capsule (adults aged ≤49 years) or 2 capsules (adult aged ≥50 years) daily of a probiotic including Lactobacillus acidophilus CL1285, Lacticaseibacillus (Lactobacillus) casei LBC80R, and Lacticaseibacillus (Lactobacillus) rhamnosus CLR2 (Bio-K+ 50 Billion [50 billion colony-forming units per cap…”
Self-citationTartof, S. Y., Rieg, G. K., Wei, R. X., Tseng, H. F., Jacobsen, S. J., & Yu, K. C. (2015) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2015.220 · Cited by 52
Cited by
Lactobacillus Bacteremia and Probiotics: A Review
Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V. (2023) · Microorganisms · doi:10.3390/microorganisms11040896 · Cited by 156
“rhamnosus CLR2, BioK+®) were followed for any complications of probiotic use [65,66].”
BackgroundSelf-citationDjukovic, A., Garzón, M. J., Canlet, C., Cabral, V., Lalaoui, R., García-Garcerá, M., Rechenberger, J., Tremblay-Franco, M., Peñaranda, I., Puchades-Carrasco, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33313-w · Cited by 85
Probiotics: insights and new opportunities for Clostridioides difficile intervention
Pal, R., Athamneh, A. I. M., Deshpande, R., Ramirez, J. A. R., Adu, K. T., Muthuirulan, P., Pawar, S., Biazzo, M., Apidianakis, Y., Sundekilde, U. K., et al. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2072705 · Cited by 50
Clostridioides difficile infection in infants: a case report and literature review
Li, Z., Dong, N., Hao, J., Ouyang, Z., Qiang, C., Yang, Y., Mi, C., Niu, Y., Yang, J., Wen, B., et al. (2023) · Gut Pathogens · doi:10.1186/s13099-023-00552-1 · Cited by 8
McFarland, L. V., Goldstein, E. J. C., & Kullar, R. (2023) · Microorganisms · doi:10.3390/microorganisms11061534 · Cited by 7
Self-citation
Metadata
- Authors
- Maziade, P.-J., Ship, N., Sniffen, J. C., & Goldstein, E. J. C.
- Affiliations
- Centre intégré de santé et de services sociaux de Lanaudière (CA)
- Bio-K+ International (Canada) (CA)
- AdventHealth Orlando (US)
- R. M. Alden Research Laboratory, Santa Monica, California, USA
- Corresponding author
- Maziade, Pierre-Jean
- ORCID
- Sniffen, Jason C
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-05-09
- Volume
- 73
- Issue
- 8
- Pages
- 1524-1527
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC8528394
- OpenAlex
- W3162038454
- Cited by
- 15
- References
- 12
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 7 · 2022: 2 · 2021: 3
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Keywords
- Clostridium difficile infection, probiotics, Lactobacillus, antibiotic-associated diarrhea, hospital pharmacy policy, nosocomial infection prevention
- MeSH terms
- Clostridioides, Anti-Bacterial Agents, Clostridium Infections, Diarrhea, Humans, Lactobacillus, Pharmacy, Clostridioides difficile, Probiotics, Policy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy. https://app.cochat.ai/papers/10.1093/cid/ciab414
- The paper
- Maziade, P.-J., Ship, N., Sniffen, J. C., & Goldstein, E. J. C. (2021). Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab414
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.